2018年12月12日，领星生物科技（上海）有限公司宣布完成由挚信资本领投，General Oriental和金浦健康基金跟投的3000万美金A+轮融资。
On December 12, GenomiCare Biotechnology (Shanghai) Co., Ltd. announced it had completed series A+ financing round with additional $30 million US dollars. The Investment was led by Trustbridge Partners and followed by General Oriental and GP Healthcare Capital.
